https://www.selleckchem.com/pr....oducts/Resveratrol.h
Immune checkpoint inhibitors (ICIs) have dramatically changed the treatment landscape for advanced melanoma, but their use in older patients remains understudied. An age-related decline in immune function is of concern when treating older patients because host immune factors can influence clinical outcomes with immunotherapy. Therefore, we aimed to evaluate the effectiveness of ICIs in patients 65years and older. Using the SEER-Medicare data, we evaluated survival by first systemic treatment type in a retrospective cohort study of p
Like
Comment
Share
